Compare ING Groep NV (ING) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ING Groep NV vs Sana Biotechnology Inc — how do they compare? ING Groep NV trades at $33.37 (market cap $93.76B), while Sana Biotechnology Inc trades at $2.79 (market cap $836.71M). The key difference: ING Groep NV is far larger — about 112.1× Sana Biotechnology Inc's market cap, and ING Groep NV pays a 3.95% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold ING Groep NV for 94 Days and Sana Biotechnology Inc for 23 Days on average.
| ING | SANA | |
|---|---|---|
Market Cap | $93.76B | $836.71M |
Volume | 4,620,220 | 4,507,444 |
Sector | Financials | Health |
52-Week High | $37.27 | $5.92 |
52-Week Low | $23.66 | $2.68 |
Typical Hold Time | 94 Days | 23 Days |
Enterprise Value | $236.48B | $749.96M |
Dividend Yield | 3.95% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ING trades at $33.43, down 1.44% today, with technical indicators showing bearish momentum despite recent earnings beats. The company reported strong Q2 2026 results with revenue growth and raised 2027 ROE targets above 16%. Valuation metrics show a P/E of 12.86 and P/B of 1.68, while analyst consensus remains strongly positive with 64.7% buy ratings.
ING presents a compelling investment case with solid profitability (28.3% net margin) and consistent earnings outperformance, though negative cash flow trends and regulatory challenges in Australia warrant caution. The stock's current technical weakness may offer entry opportunities for long-term investors attracted by the company's growth trajectory and dividend yield.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
